Endari is under clinical development by Emmaus Life Sciences and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Endari’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Endari overview

Glutamine (Endari) is an amino acid. It is formulated as powder for solution for oral route of administration. Glutamine is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.

It is under development for the treatment of sickle cell disease in pancreatic ductal adenocarcinoma and for type II diabetes. It was also under development for diverticulosis.

Emmaus Life Sciences overview

Emmaus Life Sciences (Emmaus) is a commercial-stage biopharmaceutical company. It is involved in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases and is primarily focusing on its product development efforts in Sickle Cell Disease, a genetic disorder. The company’s commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has established several collaborative relationships for commercialization and distribution of its product to selected pharmacies and hospitals. Emmaus is headquartered in Torrance, California, the US.

For a complete picture of Endari’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.